A Randomized, One-Year Clinical Trial Comparing the Efficacy of Topiramate, Flunarizine, and a Combination of Flunarizine and Topiramate in Migraine Prophylaxis
Version of Record online: 10 JAN 2012
Wiley Periodicals, Inc.
Volume 13, Issue 1, pages 80–86, January 2012
How to Cite
Luo, N., Di, W., Zhang, A., Wang, Y., Ding, M., Qi, W., Zhu, Y., Massing, M. W. and Fang, Y. (2012), A Randomized, One-Year Clinical Trial Comparing the Efficacy of Topiramate, Flunarizine, and a Combination of Flunarizine and Topiramate in Migraine Prophylaxis. Pain Medicine, 13: 80–86. doi: 10.1111/j.1526-4637.2011.01295.x
Conflict of interest: None.
The first author and corresponding author contributed equally.
- Issue online: 10 JAN 2012
- Version of Record online: 10 JAN 2012
- Combination Therapy;
Objectives. The objective of this study was to observe the efficacy, safety, and side effects of a combination of flunarizine plus topiramate compared with either flunarizine and or toparamate alone for migraine prophylaxis.
Methods. Out of 150 patients with migraine recruited into the study and randomly assigned to one of three conditions, 126 completed the trial in their group: flunarizine (39), topiramate (44), and flunarizine plus topiramate (43). Patient information was assessed at enrollment and at follow-up visits at the end of months 1–3, 6, 9, and 12. The primary measure of efficacy reduction in mean monthly migraine frequency of at least 50% as compared with baseline. Secondary efficacy parameters included reduction in mean monthly migraine days and severity of headache. Side effects were compared in the three groups by recording adverse reactions and weight changes.
Results. The proportion whose monthly headache frequency decreased more than 50% was 66.7% (26/39) in the flunarizine group, 72.7% (32/44) in the topiramate group and 76.7% (33/43) in the combination group, respectively (P = 0.593). The mean monthly days and severity of headache in the three groups also declined and was more significant in the flunarizine plus topiramate group than in the flunarizine group and the topiramate group (P < 0.05). In the flunarizine group, the average weight change was 0.6 kg. Topiramate was associated with a mean weight loss was of −0.9 kg in the topiramate group and −0.2 kg in the flunarizine plus topiramate group.
Conclusion. Flunarizine, topiramate, and the combination of flunarizine with topiramate are all effective and have good tolerability in migraine prophylaxis. Adding topiramate to flunarizine may reduce the latter's impact on body weight.